JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2025.
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JB Chemicals & Pharmaceuticals reported FY25 audited results with standalone revenue from operations of ₹3,72,292 lakhs, up about 13% from ₹3,29,864 lakhs in FY24. Standalone net profit after tax rose to ₹65,254 lakhs (FY24: ₹54,336 lakhs), a ~20% increase, with basic EPS of ₹42.00 vs ₹35.07. On a consolidated basis, revenue grew to ₹3,91,799 lakhs and net profit to ₹65,958 lakhs, both posting healthy double-digit growth. The Board recommended a final dividend of ₹7 per share for FY25. Auditor Deloitte Haskins & Sells LLP issued an unmodified (clean) opinion on both standalone and consolidated results.
Strong double-digit growth in both revenue and profit, clean audit opinion, and a healthy dividend make this a positive result for shareholders. The company also significantly reduced its current borrowings, strengthening the balance sheet, which should support investor confidence.